AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies

INDIANAPOLIS, April 24, 2018 -- (Healthcare Sales &Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc subgroup analysis which demonstrated efficacy of galcanezumab in patients with episodic and chronic migrain... Biopharmaceuticals, Neurology Eli Lilly, galcanezumab, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

ConclusionA small proportion of ED patients discharged with nonspecific diagnoses of headache or back pain returned with a serious neurologic condition or inhospital death within 30 days.
Source: Annals of Emergency Medicine - Category: Emergency Medicine Source Type: research
ConclusionDental implants complications are not uncommon. managing such complications are important to prevent serious complications. Non dental manifestations can also occur, such as this case, where chronic headache and sinusitis were observed. Accurate locating of the specific site of implant placement and knowledge of the anatomical landmark are important. Displaced dental implants into the maxillary sinus must be removed as soon as possible to avoid further complications.
Source: The Saudi Dental Journal - Category: Dentistry Source Type: research
Publication date: Available online 21 February 2019Source: Neuroimaging Clinics of North AmericaAuthor(s): Claudia F.E. Kirsch
Source: Neuroimaging Clinics of North America - Category: Radiology Source Type: research
A 72-year-old man presents with a severe headache that began suddenly a few hours prior. Can you make the correct diagnosis?Osmosis
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news
AbstractBackgroundNovel therapeutic options with improved efficacy and safety profiles are needed for the prophylaxis of migraine. In recent years, the inhibition of calcitonin gene-related peptide (CGRP) signaling has attracted growing interest in the pharmacological research on migraine. Erenumab is the first fully human monoclonal antibody directed against the CGRP receptor to be approved for use in migraineurs.ObjectiveTo evaluate the efficacy and safety of erenumab as preventive treatment in patients with migraine using meta-analytical techniques.MethodsRandomized, placebo-controlled, single- or double-blinded trials ...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
AbstractPurpose of ReviewAs ambulatory surgery has become increasingly more common, the appropriate management of anticoagulation therapy in patients undergoing invasive procedures has become progressively more relevant to healthcare professionals. The purpose of this literature review is to provide an overview of current common anaticoagulants and their pharmacological properties and to evaluate recent relevant literature and bridging therapy and provide recommendations on risk-guided therapy.Recent FindingsWith the development of new drugs and the advancing study and practice of anticoagulation use, clinicians must keep ...
Source: Current Pain and Headache Reports - Category: Neurology Source Type: research
AbstractPurpose of ReviewThe treatment of debilitating pain and loss of function secondary to lumbar stenosis is in high demand with the aging patient population. Options, including epidural steroid injections (ESIs) and medication therapy, are limited and it is unclear if they provide any functional improvements. In this prospective study, we evaluate functional outcomes in older adults with symptomatic lumbar stenosis treated with ESIs compared to those managed with medications by introducing the Short Physical Performance Battery (SPPB). Our study was IRB-approved and included 16 patients, 68 to 83  years old, with...
Source: Current Pain and Headache Reports - Category: Neurology Source Type: research
Publication date: Available online 20 February 2019Source: Neuroimaging Clinics of North AmericaAuthor(s): Shahram Hadidchi, Wesley Surento, Alexander Lerner, Chia-Shang Jason Liu, Wende N. Gibbs, Paul E. Kim, Mark S. Shiroishi
Source: Neuroimaging Clinics of North America - Category: Radiology Source Type: research
ABSTRACT Migraine is a burdensome disorder. Current treatments are far from ideal. Recent knowledge has been indicating targets whose antagonism may improve efficacy. It is particularly true with the calcitonin gene-related peptide (CGRP) and the monoclonal antibodies anti-CGRP can interfere with this pathway and decrease the frequency of migraine attacks. Erenumab, fremanezumab and galcanezumab have recently been approved and eptinezumab is likely to be, soon. Although efficacy figures were not spectacular, tolerability and potential higher adherence were noteworthy. However, caution must be exercised. The time frame afte...
Source: Arquivos de Neuro-Psiquiatria - Category: Neurology Source Type: research
ConclusionSince there is often times a clinico-radiological discordance they are generally incidental findings in majority of cases. While complete surgical excision is the treatment of choice for the symptomatic cysts, cystic fluid diversion presents a better compromise nevertheless in cases where this may not be achieved.
Source: Interdisciplinary Neurosurgery - Category: Neurosurgery Source Type: research
More News: Brain | Headache | Marketing | Migraine | Neurology | Pharmaceuticals